Moderna teams up with Recordati to commercialize rare disease therapy

AstraZeneca pledges $15 billion investment in China through 2030

UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."

BioMed X launches groundbreaking AI-driven diabetes research in Barbados

With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio

Fides launches imaging CRO focused on early-phase clinical decision-making

Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors

INDIA-EU FTA unlocks access to $572.3 billion EU pharmaceuticals & medical devices market

Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents

Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial

The Phase III programme, Enith1 and Enith2, is expected to launch this quarter

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites

Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research

The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results

Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies